BioMarin Pharmaceutical (BMRN) Insider Trading & Ownership $66.83 +0.34 (+0.51%) As of 01/3/2025 05:21 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends BioMarin Pharmaceutical (NASDAQ:BMRN) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.85%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)7Amount OfInsider Selling(Last 12 Months)$15.60 M Get BMRN Insider Trade Alerts Want to know when executives and insiders are buying or selling BioMarin Pharmaceutical stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address BMRN Insider Buying and Selling by Quarter Ad Behind the MarketsCould this AI-powered “God Key” soar 36,996%??A new AI breakthrough is disrupting the $4.5 trillion healthcare industry. It's a breakthrough we call the AI "God Key"... and it's setting the stage for unprecedented breakthroughs in medicine.Click here for the ticker >>> BioMarin Pharmaceutical Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/12/2024Charles Greg GuyerEVPSell5,278$66.37$350,300.86 5/30/2024Brian MuellerCFOSell5,000$75.19$375,950.00 5/28/2024George Eric DavisEVPSell40,850$74.51$3,043,733.50 5/9/2024Jean Jacques BienaimeDirectorSell20,000$81.62$1,632,400.00 5/2/2024George Eric DavisEVPSell1,850$85.01$157,268.50 4/12/2024Jean Jacques BienaimeDirectorSell20,000$91.26$1,825,200.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 4/10/2024Erin BurkhartCAOSell2,286$90.00$205,740.00 3/28/2024George Eric DavisEVPSell24,602$88.34$2,173,340.68 3/5/2024Henry J FuchsInsiderSell35,341$85.18$3,010,346.38 3/5/2024Jean Jacques BienaimeDirectorSell1,000$85.51$85,510.00 3/5/2024Jeffrey Robert AjerEVPSell4,000$87.07$348,280.00 2/27/2024Jean Jacques BienaimeDirectorSell1,000$90.35$90,350.00 2/9/2024Jean Jacques BienaimeDirectorSell15,000$88.28$1,324,200.00 1/9/2024Jean Jacques BienaimeDirectorSell10,000$98.19$981,900.00 (Data available from 1/1/2013 forward) BMRN Insider Trading Activity - Frequently Asked Questions Who is on BioMarin Pharmaceutical's Insider Roster? The list of insiders at BioMarin Pharmaceutical includes Brian Mueller, Charles Greg Guyer, Dennis Slamon, Erin Burkhart, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Richard A Meier, and V Bryan Lawlis. Learn more on insiders at BMRN. What percentage of BioMarin Pharmaceutical stock is owned by insiders? 1.85% of BioMarin Pharmaceutical stock is owned by insiders. Learn more on BMRN's insider holdings. Which BioMarin Pharmaceutical insiders have been selling company stock? The following insiders have sold BMRN shares in the last 24 months: Brian Mueller ($662,200.00), Charles Greg Guyer ($350,300.86), Erin Burkhart ($205,740.00), George Eric Davis ($7,669,671.88), Henry J Fuchs ($4,095,506.38), Jean Jacques Bienaime ($18,686,610.00), Jeffrey Robert Ajer ($6,467,580.00), and V Bryan Lawlis ($825,265.00). How much insider selling is happening at BioMarin Pharmaceutical? Insiders have sold a total of 415,971 BioMarin Pharmaceutical shares in the last 24 months for a total of $38,962,874.12 sold. BioMarin Pharmaceutical Key ExecutivesMr. Alexander Hardy (Age 55)President, CEO & Director Compensation: $1.72MMr. Brian R. Mueller (Age 50)CFO & Executive VP Compensation: $1.07MDr. C. Greg Guyer Ph.D. (Age 62)Executive VP & Chief Technical Officer Compensation: $1.11MMr. Jeffrey Robert Ajer (Age 62)Executive VP & Chief Commercial Officer Compensation: $1.1MDr. Henry J. Fuchs M.D. (Age 66)Ph.D., President of Worldwide Research & Development Compensation: $1.41MMs. Erin Burkhart (Age 45)Group VP & Chief Accounting Officer Dr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentTraci McCartyGroup Vice President of Investor RelationsMr. George Eric Davis (Age 53)Executive VP, Chief Legal Officer, General Counsel & Secretary Compensation: $1.23MMs. Humaira SerajuddinSenior VP & Chief Marketing Officer More Insider Trading Tools from MarketBeat Related Companies ALNY Insider Buying BIIB Insider Buying UTHR Insider Buying NBIX Insider Buying INCY Insider Buying EXAS Insider Buying EXEL Insider Buying RGEN Insider Buying MDGL Insider Buying HALO Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Are Selling, But These 3 Stocks Are Must-Buys3 Stocks That Wall Street Insiders Can’t Stop BuyingAppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the Millions This page (NASDAQ:BMRN) was last updated on 1/4/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioMarin Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
